Quantum BioPharma (NASDAQ: QNTM) has entered a Study Start-Up Agreement (SUA) with the clinical research business of Thermo Fisher Scientific to implement its Phase 2 clinical trial of Lucid-21-302 (Lucid-MS) for multiple sclerosis (MS). The agreement initiates formal study start-up activities following FDA clearance to proceed with the trial. Thermo Fisher will support study start-up and related clinical research services through its PPD Clinical Research Business. The news, first reported by NEWMEDIAWIRE, signals a critical operational milestone for the biopharmaceutical company.
The randomized, double-blind, placebo-controlled Phase 2 trial will evaluate the efficacy, safety, and tolerability of Lucid-MS in people with progressive forms of MS using clinical and radiological endpoints. Lucid-MS is an investigational, first-in-class New Chemical Entity designed to provide neuroprotection by inhibiting demyelination through targeting protein arginine deiminase 2 (PAD2), an enzyme implicated in myelin degradation. This mechanism differentiates Lucid-MS from existing MS therapies, which primarily modulate the immune system rather than directly protect myelin.
Multiple sclerosis is a chronic, often progressive disease in which the immune system attacks the protective myelin sheath covering nerve fibers, leading to symptoms such as fatigue, mobility impairment, and cognitive decline. Progressive forms of MS currently have limited treatment options, and no therapy has been approved specifically to prevent or reverse demyelination. If Lucid-MS proves effective in Phase 2, it could represent a paradigm shift in how progressive MS is managed, offering a neuroprotective approach that complements existing immunomodulatory treatments.
Quantum BioPharma is dedicated to building a portfolio of innovative assets and biotech solutions for challenging neurodegenerative and metabolic disorders and alcohol misuse disorders. Through its wholly owned subsidiary, Lucid Psycheceuticals Inc., Quantum is focused on the research and development of its lead compound, Lucid-MS. The compound is a patented new chemical entity shown to prevent and reverse myelin degradation, the underlying mechanism of multiple sclerosis, in preclinical models. The company invented UNBUZZD and spun out its OTC version to Unbuzzd Wellness Inc., retaining a 19.84% ownership stake as of March 31, 2026, along with royalty payments of 7% of sales until payments total $250 million, after which the royalty drops to 3% in perpetuity. Quantum also retains 100% of the rights to develop similar products or alternative formulations specifically for pharmaceutical and medical uses.
The agreement with Thermo Fisher's PPD business is expected to accelerate the trial's launch by leveraging Thermo Fisher's global clinical research infrastructure and expertise. For investors and industry observers, the deal reduces execution risk and underscores Quantum's commitment to advancing Lucid-MS through clinical development. The full press release can be viewed at https://ibn.fm/CZH9U. The latest news and updates relating to QNTM are available in the company's newsroom at https://ibn.fm/QNTM. As with any clinical-stage biopharmaceutical endeavor, forward-looking statements involve risks and uncertainties that could cause actual results to differ materially from expectations.
